A carregar...
Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI–Mediated Anticancer Activity in NSCLC
Epidermal growth factor receptor (EGFR) mutations were found in 30%-40% of non–small cell lung cancer (NSCLC) patients, who often responded well to EGFR tyrosine kinase inhibitors (EGFR-TKIs) as exemplified by erlotinib and gefitinib in the past decades. However, EGFR mutation-led drug resistance us...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2019-11-01
|
| Colecção: | Translational Oncology |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S1936523319302633 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|